Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

Name: Αlpha¹ Rigor Record — Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Item: Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Rating: 100
Author: Αlpha¹

Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.75★ (Strong), 0 critical, 5 high issues for “Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.75 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced2 types

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously conducted and transparently reported phase 3 randomized controlled trial with strong scientific premise, detailed methods, and appropriate statistical analysis. Minor reporting gaps exist (explicit power analysis, outlier handling, exact p-values for exploratory analyses, and statistical assumption verification), but none undermine the validity of the findings. The paper is well-suited for publication and the post-publication robustness is high.

Both reviewers independently scored all eight dimensions and agreed on the status of each, with only minor sub-criterion differences in study design and statistical analysis. The study type is interventional (phase 3 RCT). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification recomputed 5 reported tests/effect estimates, all consistent; coverage is limited to tests with test statistics/df or effect estimates with CIs, so other statistics remain unverified. The citation check found 1 reference not found in registry (potential fabrication signal), which is addressed in the action items.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Reporting

Eight Dimensions8 pass

The paper cites numerous prior studies establishing HER2 as a therapeutic target and the development of T-DXd and T-DM1. It acknowledges strengths and weaknesses of prior work, including the EMILIA trial and CLEOPATRA trial. The rationale for comparing T-DXd to T-DM1 is logically presented based on their differing mechanisms and drug-to-antibody ratios. Limitations of prior analyses (e.g., median OS not reached) are explicitly addressed as motivation for this updated analysis.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on HER2-positive breast cancer and the development of T-DXd, and clearly links this to the study's objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is characterized by amplification of the HER2 (ERBB2) gene and/or overexpression of the HER2 protein, which stimulates cell proliferation, survival, differentiation, angiogenesis and invasion.”

direct quote[Introduction, last paragraph]

“We report on an exploratory analysis of DESTINY-Breast03 (data cutoff, 20 November 2023), with updated efficacy, including median OS, and safety data with longer follow-up.”